177 related articles for article (PubMed ID: 18193496)
1. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
Schackman BR; Ribaudo HJ; Krambrink A; Hughes V; Kuritzkes DR; Gulick RM
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):547-54. PubMed ID: 18193496
[TBL] [Abstract][Full Text] [Related]
2. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
Bednasz CJ; Venuto CS; Ma Q; Daar ES; Sax PE; Fischl MA; Collier AC; Smith KY; Tierney C; Yang Y; Wilding GE; Morse GD
Ther Drug Monit; 2017 Dec; 39(6):596-603. PubMed ID: 29135907
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Robbins GK; De Gruttola V; Shafer RW; Smeaton LM; Snyder SW; Pettinelli C; Dubé MP; Fischl MA; Pollard RB; Delapenha R; Gedeon L; van der Horst C; Murphy RL; Becker MI; D'Aquila RT; Vella S; Merigan TC; Hirsch MS;
N Engl J Med; 2003 Dec; 349(24):2293-303. PubMed ID: 14668455
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Paredes R; Lalama CM; Ribaudo HJ; Schackman BR; Shikuma C; Giguel F; Meyer WA; Johnson VA; Fiscus SA; D'Aquila RT; Gulick RM; Kuritzkes DR;
J Infect Dis; 2010 Mar; 201(5):662-71. PubMed ID: 20102271
[TBL] [Abstract][Full Text] [Related]
7. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
[TBL] [Abstract][Full Text] [Related]
8. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
Lehmann DS; Ribaudo HJ; Daar ES; Gulick RM; Haubrich RH; Robbins GK; de Bakker PI; Haas DW; McLaren PJ
Pharmacogenet Genomics; 2015 Feb; 25(2):51-9. PubMed ID: 25461247
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Kumar P; DeJesus E; Huhn G; Sloan L; Small CB; Edelstein H; Felizarta F; Hao R; Ross L; Stancil B; Pappa K; Ha B;
BMC Infect Dis; 2013 Jun; 13():269. PubMed ID: 23741991
[TBL] [Abstract][Full Text] [Related]
11. Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.
Grady BJ; Torstenson ES; McLaren PJ; DE Bakker PI; Haas DW; Robbins GK; Gulick RM; Haubrich R; Ribaudo H; Ritchie MD
Pac Symp Biocomput; 2011; ():253-64. PubMed ID: 21121053
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Cohen CJ; Molina JM; Cahn P; Clotet B; Fourie J; Grinsztejn B; Wu H; Johnson MA; Saag M; Supparatpinyo K; Crauwels H; Lefebvre E; Rimsky LT; Vanveggel S; Williams P; Boven K; ;
J Acquir Immune Defic Syndr; 2012 May; 60(1):33-42. PubMed ID: 22343174
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
[TBL] [Abstract][Full Text] [Related]
14. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
15. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
[TBL] [Abstract][Full Text] [Related]
16. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
[TBL] [Abstract][Full Text] [Related]
17. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
[TBL] [Abstract][Full Text] [Related]
18. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
Demeter LM; DeGruttola V; Lustgarten S; Bettendorf D; Fischl M; Eshleman S; Spreen W; Nguyen BY; Koval CE; Eron JJ; Hammer S; Squires K
HIV Clin Trials; 2008; 9(1):11-25. PubMed ID: 18215978
[TBL] [Abstract][Full Text] [Related]
19. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
